Multisite Observational Maternal and Infant Study for COVID-19 (MOMI-Vax)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05031468|
Recruitment Status : Active, not recruiting
First Posted : September 2, 2021
Last Update Posted : April 19, 2022
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Flor Munoz, Baylor College of Medicine
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Active, not recruiting|
|Estimated Primary Completion Date :||December 2022|
|Estimated Study Completion Date :||July 2023|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge K, Mulligan MJ, Parameswaran L, Kelly C, Olsen-Chen C, Novak RM, Brady RC, Pasetti M, DeFranco E, Gerber JS, Shriver M, Suthar MS, Moore K, Coler R, Berube B, Kim SH, Piper JM, Miller A, Cardemil C, Neuzil KM, Beigi R; DMID Study Group. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004). medRxiv. 2022 Jun 13. pii: 2022.06.13.22276354. doi: 10.1101/2022.06.13.22276354.
Munoz FM, Beigi RH, Posavad CM, Richardson BA, Chu HY, Bok K, Campbell J, Cardemil C, DeFranco E, Frenck RW, Makhene M, Piper JM, Sheffield J, Miller A, Neuzil KM. Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol. BMC Pregnancy Childbirth. 2022 May 12;22(1):402. doi: 10.1186/s12884-022-04500-w.